Jefferies analyst Gena Wang reiterated a Buy rating and lifted her price target on bluebird bio (NASDAQ: BLUE) to $88.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

bluebird bio (BLUE) PT Raised to $87 at Maxim GroupDecember 1, 2016 11:45 AM bluebird bio (BLUE) PT Raised to $85 at Leerink PartnersDecember 1, 2016 11:26 AM BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple MyelomaDecember 1, 2016 7:51 AM bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean SafetyDecember 1, 2016 6:18 AM bluebird bio (BLUE) Reports Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product CandidateNovember 30, 2016 5:28 PM bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple MyelomaNovember 30, 2016 5:27 PM